CellExSys

CellExSys is a clinical-stage biotechnology company dedicated to developing "off-the-shelf" allogeneic T-cell therapies for the treatment of life-threatening viral infections. The company's proprietary platform generates virus-specific T-cells (VSTs) that target common opportunistic viruses such as CMV, EBV, and BKV, which frequently affect immunocompromised transplant recipients. By utilizing a bank of pre-manufactured, partially HLA-matched cells, CellExSys aims to provide rapid, effective treatment without the delays associated with autologous therapies. Their pipeline includes multi-virus targeting products currently undergoing clinical evaluation to improve outcomes for patients with limited therapeutic options.